Koers Arca Biopharma Inc Nasdaq
Aandelen
US00211Y2090
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 24,5 mln. 22,4 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -9 mln. -8,23 mln. | Nettowinst (verlies) 2023 | -5 mln. -4,57 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 42,06 mln. 38,47 mln. | Nettoliquiditeiten 2023 | 37,15 mln. 33,98 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-3,44
x | K/w-verhouding 2023 |
-4,59
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Keuer
CEO | Chief Executive Officer | 65 | 01-10-06 |
C. Dekker
DFI | Director of Finance/CFO | 60 | 10-05-21 |
Sharon Perry
LAW | General Counsel | - | 01-01-08 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Anders Hove
BRD | Director/Board Member | 58 | 16-02-17 |
Robert Conway
CHM | Chairman | 70 | 03-09-13 |
Linda Grais
BRD | Director/Board Member | 68 | 01-05-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,03% | 126 mld. | |
+23,61% | 117 mld. | |
+23,26% | 27,52 mld. | |
-18,07% | 20,87 mld. | |
-15,13% | 17,01 mld. | |
-14,81% | 16,26 mld. | |
+9,78% | 14,56 mld. | |
-46,10% | 15,09 mld. | |
+52,34% | 13,89 mld. |